Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01136746 · ClinicalTrials.gov registry record · Phase 3
Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 16
- Enrollment target
NCT01136746 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 16 participants.
The verdict
NCT01136746, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the use of insulin glargine plus insulin lispro to human regular insulin for treatment of hyperglycemia in the hospital setting in patients without known prior history of diabetes.
Interventions
- DRUG Insulin glargine
- DRUG Insulin lispro
- DRUG Human regular insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2011-03 |
| Est. Completion | 2011-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01136746
The ClinicalTrials.gov registry entry for NCT01136746 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Insulin glargine is the first listed.
NCT01136746 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01136746 about?
NCT01136746 is a clinical study titled "Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin". The purpose of this study is to compare the use of insulin glargine plus insulin lispro to human regular insulin for treatment of hyperglycemia in the hospital setting in patients without known prior history of diabetes.
What is the current status of trial NCT01136746?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 16 participants. The study started on 2011-03. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01136746?
The interventions under investigation include: Insulin glargine (DRUG), Insulin lispro (DRUG), Human regular insulin (DRUG).
Who is sponsoring clinical trial NCT01136746?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.